China Leads Strong AstraZeneca Emerging Markets Charge In Q1
Despite a fall in overall revenue, emerging markets continued to perform strongly for AstraZeneca in the first quarter, becoming the UK group's single largest sales region globally, driven mainly by China.
You may also be interested in...
For the first time, new product launches start driving growth for AstraZeneca in China where a new national reimbursement scheme is likely to further expand market access to five products but that comes with a steep price cut.
Given the host of recent and planned policy and regulatory changes in China, the traditional lines between multinational and local companies in the country will become increasingly blurred. These who know how to innovate in different ways in the fast-changing environment will have the most to gain, says the head of one major pharma industry trade group.
After a long seven-year hiatus, China is finally moving to update its national reimbursement drug list, but the process will involve huge numbers of experts and the benefits of inclusion may not be as immediate or as extensive as appear at first sight.